

including coagulopathy.⁴ Fortunately, our patient was started on anticoagulants and had no known thrombotic complications. Vaccination status should not preclude suspicion for MIS-C. Additional surveillance is needed to determine whether HbSS is associated with increased vulnerability to MIS-C following vaccination.

REFERENCES

1. Frenc RW Jr, Klein NP, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents. *N Engl J Med*. 2021;385:239–250.
2. Siegel DA, Reses HE, Cool AJ, et al.; MAPW1. Trends in COVID-19 cases, emergency department visits, and hospital admissions among children and adolescents aged 0-17 years - United States, August 2020-August 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70:1249–1254.
3. Salzman MB, Huang CW, O'Brien CM, et al. Multisystem inflammatory syndrome after SARS-CoV-2 infection and COVID-19 vaccination. *Emerg Infect Dis*. 2021;27:1944–1948.
4. Español MG, Gardner RV, Alicea-Marrero MM, et al. Multisystem inflammatory syndrome in a pediatric patient with sickle cell disease and covid-19. *J Pediatr Hematol Oncol*. Publish online May 18, 2021;doi: 10.1097/MPH.0000000000002191.